To acquire China National Medical Products Administration (NMPA)’s marketing authorization for medical devices, companies need to file or register the…
On Jan. 1, 2023, China National Medical Products Administration (NMPA) started to require that all documents for drug registration applications, as we…
On Mar. 3, 2023, China Center for Drug Evaluation (CDE) released six Q&As on drug master file (DMF) filing (Q&A No. 1-2) and drug application’…
By a notice issued on April 7, 2023, the Chinese Ministry of Ecology and Environment (MEE) made public 3,069 new chemical record registrations that we…
On January 19, 2023, the General Office of China’s Ministry of Agriculture and Rural Affairs (MOARA) issued a notice on the establishment of a coordin…
HANGZHOU, 24 February 2023 – REACH24H is proud to announce the release of its 2022 Annual Report, showcasing a year of achievements and mileston…
After consulting on the draft in Nov. 2022, China National Medical Products Administration (NMPA) released the Administrative Rules on Supervising Dru…
On May 13, 2021, China National Medical Products Administration (NMPA) released the Good Pharmacovigilance Practices (GVP), which has been effective s…
On Jan. 11, 2023, China Center for Drug Evaluation (CDE) released 10 Q&As, including nine questions on the electronic submission of drug applicati…
In July 2018, China optimized the clinical trial applications (CTA) / investigational new drug (IND) applications\’ review and approval procedur…
